Member Info for Saintsmith

Is 15 still your magic number K ?

An endorsement from Elon musk would help I would think ;)

There might be room for more than one supplier if they are rolling it out nationwide or even worldwide . Side by side with vaccines as previously speculated on this board .
Fingers crossed .

Below article from Novacyt insider aug 2020.

The last paragraph is very interesting and shows through microgen whom we are involved with have the ability to produce 3 million fingerprick antibody tests a month.

We could be involved after all :)

“This month the British Government began a rollout of antibody home finger prick tests, which although are currently only available to key workers due to capacity constraints – it is understood will be made more widely available once the current UK lab expansion has progressed and more suppliers have been found.

The test images sent to us yesterday by popular investor RainCloud help to understand why the Government has chosen this method. There is little to no room for error as the participants aren’t performing the test themselves, they are simply extracting a little blood and returning it by post to the lab with the result texted back within 24 hours.

RainCloud is currently performing the test as part of their company’s screening routine.
Once returned to labs, the blood sample can be processed in large well-plate ELISA tests, ranging in sizes from 90 to 480 tubes. Some labs are automated, removing the need for pipetting which increases the throughput – ideal for mass testing once fully rolled out. It is expected that the UK Government will adopt two methods of antibody testing, adding LFT devices which together with the lab tests should provide epidemiologists with wide enough screening to understand how the virus has spread through the population and possibly – how many may have developed immunity.

Microgen’s new 480 plate antibody test is called the SARS-CoV-2-EIA-IgG, and is designed for use in vaccine trials, mass population screening and 480 tests can be performed in 90 minutes – a throughput of 18 seconds per test. Novacyt will produce 3 million of the new Microgen antibody tests per month and has the ability to increase should demand move beyond that initial expectation. It can be used with two sample types – blood serum and plasma – and can also be used in high-throughput automated machines to reduce manual workloads when health bodies are required to process millions of tests per month.

Bbc radio 4 mentioned a new antibody finger prick test that runs alongside vaccines.
I’ve been looking for who makes it , not found anything linking to our new antibody test yet . I don’t think we use that method of testing .

I will certainly be adding on April 6th when I can add to my Isa, my entire limit went on NCYT last year and I will be adding more .
Keep the faith clr123.
Several months ago another poster on here was very nervous and nearly sold at a loss , he listened to the good people on this board , held and was very glad he did .
Not financial advice , just my opinion .

That is good they are backing positive tests up with PCR . However they are still using LFD for initial testing . They claim it it 99.9% specific so out of 1000 people it will only miss one false positive .
No mention at all about the sensitivity ( false negatives) which are far more important as they will miss cases and allow new variants to spread as they have not been flagged up in the first place and verified by a PCR test .
When will they ever learn ?

I think the derampers were probably watching coronation street tkr234.

Operator error.
Tests not at fault .
Just the testers .

Shocking standards indeed . Badly managed and no one seems to care .
Targets implemented to the testing staff and lack of scrutiny by senior lab technicians to blame .
Wouldn’t happen on a q32

PCR stated as been the most accurate testing method right at the start of the program .

My spider sense says Wednesday 7 am for RNS ;)

@Try2buylow .
Don’t be disappointed . The last two RNS were released on Wednesdays .
Will they go for a hat trick this coming Wednesday ?

All long termers will be used to seeing a small drop after a great RNS.
It’s frustrating but you learn to relax as hopefully you have done enough research to know that this share will take off again one day .
They don’t recruit like this for nothing .
When it goes it goes and I believe we will soon be seeing all time highs .
I think a few people need to chill out and go have a busy wolverine ;)

BTW I typed the asterixs in and didn’t use a rude word .
Poetic licence may be used to fill in the blanks though ;)

“A terribly busy morning w**k”

Eh wolverine ;)

Hi k.
In the words of the great Roy Walker .
“Say what you see “
Unlike my pdf link which I don’t think you can see :(

PDF link below for your files .

https://*********************/dashboard/PortalDownloadResearchNote?id=7_2021032406202961481&token=a3fb731f-21d6-4586-a9a7-7e47d3c77568&partner=&whitelabelCompanyId=

The note is up Shaun

Latest sp Angel note below .
Copied from the website .

Company Update
Novacyt S.A. (NCYT.L*): Launch of new panel test to detect COVID-19 variants
Market Capitalisation: £512.8m; Share price: 726p; Target Price: 1,433p – BUY
• Diagnostic developer, Novacyt, is launching a new panel test which can detect multiple COVID-19 variants.
• SNPsig® VariPLEXTM is a PCR-based assay which can detect four viral variants of concern and two key mutations in a
single kit.
• The panel detects variants originally identified in the UK (20I/501Y.V1), South Africa (20H/501Y.V2), Brazil (20J/501Y.V3)
and California (20C/S.452R) as well as the N501Y and E484K mutations which are associated with increased viral
transmission and immune system escape, respectively.
• VariPLEXTM can be run on the Group’s q32 instruments and can be deployed in a near-patient settings or in a central
laboratory.
Given the concern that certain strains may impact the efficacy of COVID-19 vaccines and therapeutics, SNPsig® VariPLEXTM should support efforts to track and trace individuals to reduce transmission. The panel provides an alternative to next generation sequencing (NGS) to detect the specific variant present in a patient sample. NGS typically requires up to 14 days of off-site analysis. The Group notes that VariPLEXTM is a customisable assay and new mutations can be added to the panel. As the emergence of new variants are expected as viruses accumulate new mutations, this feature ensures the panel remains clinically relevant over time.
* SP Angel act as Nomad & Joint Broker to Novacyt